Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor

Clinical and Experimental Metastasis

Volumn 16, Issue 6, 1998, Pages 559-568

  Ma, Jianguo ^a   Zhou Li, Fei ^a   Klein Szanto, Andres ^a   Gallo, James M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Factor VIII; Glioma xenograft; VEGF

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CLONOGENESIS; CONTROLLED STUDY; DNA TRANSFECTION; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CAPILLARIES; CARMUSTINE; CELL HYPOXIA; DACARBAZINE; DNA, ANTISENSE; ENDOTHELIAL GROWTH FACTORS; GENETIC VECTORS; GLIOMA; HUMANS; LYMPHOKINES; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, NUDE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032417924     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006598419541     Document Type: Article

References (36)

1. Senger DR, Peruzzi CA, Feder J, and Dvorak HF, 1986, A high conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res, 46, 5629-32.
2. Leung DW, Cachianes G, Kuang W-J, et al. 1990, Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-9.
3. Plate KH, Breier G, Weich HA, and Rusau W, 1992, Vascular growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature, 359, 845-8.
4. Samoto K, Ikezaki K, Ono M, et al. 1995, Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res, 55, 1189-93.
5. Takahashi Y, Kitadai Y, Bucana CD, et al. 1995, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, 55, 3964-8.
6. Shweiki D, Itin A, Soffer D, and Keshet E, 1992, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843-5.
7. Namiki A, Brogi E, Kearney M, et al. 1995, Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem. 270, 31189-95.
8. Minchenko A, Bauer T, Salceda S, and Caro J, 1994, Hypoxic stimulation of vascular endothelial growth factor expression in vitro and vivo. Lab Invest, 71, 374-9.
9. Ikeda E, Achen MG, Breier G, and Risau W, 1995, Hypoxia-induced of vascular endothelial growth factor in C6 glioma cells. J Biol Chem, 270, 19761-6.
10. Goldman CK, Kim J, Wong WL, et al. 1993, Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell, 4, 121-33.
11. de Vries C, Escobedo JA, Ueno H, et al. 1992, The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-91.
12. Terman BI, Dougher-Vermazen M, Carrion ME, et al. 1992, Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Comm, 187, 1579-86.
13. Millauer B, Witzigmann-Voos S, Schnurch H, et al. 1993, High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835-46.
14. Claffery KP, and Robinson GS, 1996, Regulatiuon of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev, 15, 165-76.
15. Klagsbrun M, and D'Amore PA, 1996, Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev, 7, 259-70.
16. Terman BI, and Dougher-Vermazen M, 1996, Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev, 15, 159-63.
17. Devineni D, Klein-Szanto A, Gallo JM, 1996, Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res, 56, 1983-7.
18. Breier G, Albrecht U, Sterrer S, and Risau W, 1992, Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Develop, 114, 521-32.
19. Bradford MM, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
20. Goldberg MA, and Schneider TJ, 1994, Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth facotr and erythropoietin. J Biol Chem, 269, 4355-9.
21. Skehan P, Storeng R, Scudiero D, et al. 1990, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82, 1107-12.
22. Ma J, Verweij J, Kolker HJ, et al. 1994, Pharmacokinetic-dynamic relationship of cisplatin in vitro simulation of an iv bolus, 3h and 20 h infusion. Br J Cancer, 69, 858-62.
23. Akbasak A, Toevs CC, and Laske DW, 1996, Reconstituted basement membrane (matrilgel) enhances the growth of human glioma cell lines in nude mice. Lab Invest, 27, 23-30.
24. Pretlow TG, Delmoro CM, Dilley GG, et al. 1991, Transplantation of human carcinoma nude mice in matrigel. Cancer Res, 51, 3814-7.
25. Devineni D, Klein-Szanto A, and Gallo JM, 1996, In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2) bearing rats. Cancer Chemother, Pharmacol, 38, 499-507.
26. Gerson SL, Miller K, and Berger NA, 1985, O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest, 76, 2106-14.
27. Miller SA, Dykes DD, and Polesky HF, 1998, A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res, 16, 1215.
28. Plate KH, Breier G, Millauer B, et al. 1993, Up-regulation of vascular endothelial growth factor and its cogenate receiptor in arat glioma model of tumor angiogenesis. Cancer Res, 53, 5822-7.
29. Houck KA, Leung DW, Rowland AM, et al. 1992, Dual regulation of vascular endothelial growth factor bioavalibility by genetic and proteolytic mechanisms. J Biol Chem, 267, 26031-7.
30. Potgens AJG, Lubsen NH, van Altena MC, et al. 1995, Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Path, 146, 197-209.
31. Senger DR, Connolly DT, van de Water L, et al. 1990, Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res, 50, 1774-8.
32. Claffey KP, Brown LF, del Aguila LF, et al. 1996, Expression of vascular permeability/vascular endothelial growth factor by melanoma cells increase tumor growth, angiogenesis, and experimental metastasis. Cancer Res, 56, 172-81.
33. Mitchell EP and Schein PS, 1986, Contributions of nitrosoureas to cancer treatment. Cancer Treat Rep, 70, 31-41.
34. O'Reilly SM, Newlands ES, Glaser MG, et al. 1993, Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer, 29A, 940-2.
35. Dhodapkar M, Rubin J, Reid JM, et al. 1997, Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res, 3, 1093-100.
36. Bianchini F, Montesano R, Shuker DEG, et al. 1993, Quantification of 7-methyl-deoxyguanosine using immunoaffinity purification and HPLC with electrochemical detection. Carcinogenesis, 14, 1677-82.